Translating a better understanding of the microbiome, the large mass of micro-organisms that we all carry around in our gastrointestinal (GI) tract, our skin and elsewhere, into beneficial therapeutic products is proving to be a long and painstaking process. Still, it is one that may be attractive to researchers with a background in complex systems and processes.
That is according to Tomas de Wouters, co-founder and CEO of the five-year-old Swiss start-up, PharmaBiome, and one of In...